N/A N=249 Hyperopia Treatment Study 1 (HTS1) - Glasses vs Observation
Hyperopia
Primary: Number of Participants With Confirmation of Failure Criteria — 5; 4; 11; 18 Participants — p=0.72
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=45 Azacitidine and Entinostat in Treating Patients With Recurrent Advanced Non-Small Cell Lung Cancer
Recurrent Non-Small Cell Lung Carcinoma · Stage IIIA Non-Small Cell Lung Cancer · Stage IIIB Non-Small Cell Lung Cancer
Primary: (Phase I) Maximum Tolerated Dose (MTD) of Azacitidine When Given Together With Entinostat as Determined by Number of Participants Experiencing Dose-limiting Toxicity…
Phase 2 N=280 P03277 Dose Finding Study in Central Nervous System (CNS) Magnetic Resonance Imaging (MRI)
CNS Lesion · Blood Brain Barrier Defect
Primary: Contrast to Noise Ratio (CNR) Difference — -10.59; 2.18; 8.66; 14.45 Ratio — p=0.1858
Phase 4 N=95 Effect of Race/Ethnicity and Genes on Acetaminophen Pharmacokinetics
Pain · Fever · Hepatotoxicity
Primary: Acetaminophen Plasma Clearance Association With Race/Ethnicity — 5.3; 5.9 mL/min/kg — p=0.52
Phase 2 N=10 Effect of Double Dose of Alpha 1-antitrypsin Augmentation Therapy on Lung Inflammation.
Alpha 1 Antitrypsin Deficiency
Primary: Changes in Inflammatory Biomarkers in Bronchoalveolar Lavage Fluid — 14.3; 8.1; 10.3; 379.9 pg/ml — p=<0.05
Phase 2 N=24 Ursodiol on Insulin Sensitivity, Gastric Emptying and Body Weight With Type 2 Diabetes on Metformin
Type 2 Diabetes Mellitus
Primary: Change in Area Above Basal (AAB) for Glucose — 66458; 72566 mg/dL x min — p=0.43
Phase 2 N=21 Targeted Fusion Biopsy of the Prostate
Prostatic Neoplasms
Primary: Percentage of Cores Positive for Cancer — 32.0; 4.5 percentage of positive core samples
N/A N=51 Behavioral Study of Effects of Low-Level Light Therapy on Mood and Reaction Time
Depression
Primary: Presence and Severity of Depressive Symptoms Assessed by Center for Epidemiologic Studies - Depression Scale (CES-D) — 21.93; 22.5; 21.75 units on a the CESD scale
N/A N=19 Enalapril Maleate and Doxorubicin Hydrochloride in Treating Women With Breast Cancer
Breast Cancer
Primary: Number of Patients With Doxorubicin Plasma Concentrations Demonstrating a Significant Increase or Decrease When Doxorubicin Was Given With Enalapril as Compared to When…
Phase 4 N=11 To Evaluate the Effect of Liraglutide on Ambulatory Blood Pressure-A Pilot Study
Diabetes Mellitus, Non-Insulin-Dependent · Hypertensive Disease
Primary: Change in Systolic Blood Pressure as Measured by Ambulatory Blood Pressure Monitors. — -4.88; -5.45 mm/Hg
N/A N=42 Family Lifestyle Actions and Risk Education Study
Melanoma · Child
Primary: Percent of Participants Retained Throughout Intervention as Assessed by Session Attendance Recorded by Interventionist — 36 Participants
Phase 2 N=5 Combination Treatment With REP 2139-Ca and Pegasys in Patients With Chronic Hepatitis B
Hepatitis B, Chronic
Primary: Number of Patients Experiencing Treatment Emergent Laboratory Test Abnormalities or Adverse Events. — 5 Participants
Phase 2 N=19 A Study Evaluating the Safety and Efficacy of the LentiGlobin BB305 Drug Product in β-Thalassemia Major Participants
β-thalassemia Major
Primary: Percentage of Participants With Sustained Production of >=2.0 Grams Per Deciliter (g/dL) of Hemoglobin A (HbA) Containing βA-T87Q-globin (HbAT87Q) for the Six Months…
Phase 1 N=15 Safety Study of Enzalutamide (MDV3100) in Patients With Incurable Breast Cancer
Breast Cancer
Primary: Dose-Escalation Phase: Percentage of Participants With Dose-limiting Toxicity (DLTs) — 16.7; 0.0 percentage of participants
Phase 2 N=32 Modulation of Autophagy in Patients With Advanced/Recurrent Non-small Cell Lung Cancer - Phase II
Non-small Cell Lung Cancer · Advanced Non-small Cell Lung Cancer · Recurrent Non-small Cell Lung Cancer
Primary: Antitumor Activity, as Measured by Tumor Response Rate of Hydroxychloroquine, Paclitaxel, Carboplatin, and Bevacizumab (for Eligible Patients) in Patients With Advanced…